Prime Medicine (PRME) Operating Leases (2021 - 2026)

Prime Medicine (PRME) has 6 years of Operating Leases data on file, last reported at $114.5 million in Q1 2026.

• Quarterly Operating Leases rose 1982.04% year-over-year to $114.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.5 million (up 1982.04% YoY) and the FY2025 annual result came in at $108.3 million, up 191.26% from the prior year.
• Operating Leases improved to $114.5 million in Q1 2026, from $108.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $118.1 million in Q3 2025 to a low of $4.4 million in Q4 2023.
• A 5-year average of $47.5 million and a median of $33.6 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases slumped 83.63% — and 2026, when it soared 1982.04%.
• Tracing PRME's Operating Leases over 5 years: stood at $17.1 million in 2022, then sank by 74.45% to $4.4 million in 2023, then surged by 753.34% to $37.2 million in 2024, then surged by 191.26% to $108.3 million in 2025, then rose by 5.75% to $114.5 million in 2026.
• The last three Operating Leases figures came in at $114.5 million (Q1 2026), $108.3 million (Q4 2025), and $118.1 million (Q3 2025), per Business Quant data.